First Pacific Financial Makes New $45,000 Investment in GSK PLC Sponsored ADR (NYSE:GSK)

First Pacific Financial acquired a new stake in shares of GSK PLC Sponsored ADR (NYSE:GSK) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor acquired 1,160 shares of the pharmaceutical company’s stock, valued at approximately $45,000.

Several other institutional investors have also recently modified their holdings of GSK. Parkside Financial Bank & Trust boosted its stake in GSK by 470.1% in the fourth quarter. Parkside Financial Bank & Trust now owns 992 shares of the pharmaceutical company’s stock worth $34,000 after buying an additional 818 shares in the last quarter. Lee Danner & Bass Inc. bought a new stake in shares of GSK in the 4th quarter worth approximately $39,000. Bank Julius Baer & Co. Ltd Zurich purchased a new stake in shares of GSK in the 4th quarter valued at $40,000. Atala Financial Inc bought a new position in shares of GSK during the 4th quarter valued at $45,000. Finally, Whipplewood Advisors LLC purchased a new position in GSK in the 4th quarter worth $46,000. 15.74% of the stock is currently owned by institutional investors.

GSK Stock Performance

GSK stock opened at $38.27 on Thursday. The company has a current ratio of 0.87, a quick ratio of 0.58 and a debt-to-equity ratio of 1.21. The firm has a market cap of $78.35 billion, a P/E ratio of 19.73, a P/E/G ratio of 1.35 and a beta of 0.52. GSK PLC Sponsored ADR has a 1-year low of $31.72 and a 1-year high of $44.67. The firm has a 50-day moving average of $38.75 and a 200-day moving average of $36.89.

GSK (NYSE:GSK) last released its quarterly earnings data on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.05. The business had revenue of $10.06 billion during the quarter, compared to analysts’ expectations of $7.52 billion. GSK had a return on equity of 48.82% and a net margin of 9.89%. The business’s revenue was up 2.1% on a year-over-year basis. During the same quarter last year, the business posted $0.43 EPS. Sell-side analysts expect that GSK PLC Sponsored ADR will post 4.14 EPS for the current year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 10th. Shareholders of record on Friday, May 16th will be given a dividend of $0.4216 per share. This is an increase from GSK’s previous quarterly dividend of $0.39. This represents a $1.69 dividend on an annualized basis and a yield of 4.41%. The ex-dividend date is Friday, May 16th. GSK’s payout ratio is presently 87.11%.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Hsbc Global Res upgraded shares of GSK to a “strong sell” rating in a research report on Monday, April 28th. Wall Street Zen lowered GSK from a “buy” rating to a “hold” rating in a research note on Friday, May 30th. BNP Paribas started coverage on GSK in a report on Tuesday, April 15th. They set a “neutral” rating and a $35.25 target price for the company. Finally, Berenberg Bank reaffirmed a “hold” rating on shares of GSK in a research note on Tuesday, June 3rd. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $37.38.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.